|Mr. Raj Kannan||Pres, CEO & Director||827.55k||N/A||1964|
|Mr. Anand Varadan||Exec. VP & Chief Commercial Officer||542.27k||N/A||1967|
|Mr. John Brendan Doyle||Sr. VP, CFO & Treasurer||N/A||N/A||1977|
|Mr. Drew Enamait||VP of Fin. & Admin.||N/A||N/A||1974|
|Ms. Dawn Schottlandt CFA||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Lee G. Giguere||VP of Gen. Counsel & Sec.||N/A||N/A||1980|
|Mr. Derek Brown||VP of Marketing||N/A||N/A||N/A|
|Mr. Joe Lyons||Exec. Director of HR||N/A||N/A||N/A|
|Dr. William H. Ludlam||Sr. VP of Clinical Devel. & Medical Affairs||N/A||N/A||1966|
|Mr. David M. Schubert||Sr. VP of Regulatory & Quality||N/A||N/A||N/A|
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
Chiasma, Inc.’s ISS governance QualityScore as of 1 July 2021 is 9. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 8; Compensation: 10.